Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan
Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date. We included a total of 52 KTRs and 5...
Gespeichert in:
| Veröffentlicht in: | Hepatology Forum 2023-01, Vol.4 (1), p.14-18 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 18 |
|---|---|
| container_issue | 1 |
| container_start_page | 14 |
| container_title | Hepatology Forum |
| container_volume | 4 |
| creator | Yesil, Ezgi Ersoy Yilmaz, Yusuf Yesil, Atakan Mese, Meral Kaya, Eda Bakir, Elif Ari |
| description | Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date.
We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as the control group through prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan.
Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, respectively (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p |
| doi_str_mv | 10.14744/hf.2022.2022.0038 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9951894</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2780482865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-f66070901afd9fbbbd466e1cf70cf8cbb989963710a771b5a22aeaffb847f8663</originalsourceid><addsrcrecordid>eNpVUctuFDEQtBCIrEJ-gAPykcsEP2b84IAURQSQIoEEnC3b084aZu3F9qw038BPM9kNEVy6D11VXd2F0EtKLmkv-_7NNlwywtipEMLVE7RhcpCd5Jo9RRvKiewGpdQZuqj1ByGEKUqooM_RGReq50rpDfr9pcDBTpA84BzwDpp1eYoej0sNc_It5tTZWrOPtsGIg21twVM8QMFjrGAr4JjwzzgmWHArNtX9ZFPDBXzcR0itvsVX2Jdca1fhqGcnXNs8LniuMd3hm-hK_upteoGeBTtVuHjo5-j7zftv1x-7288fPl1f3XaeD7x1QQgiiSbUhlEH59zYCwHUB0l8UN45rbQWXFJipaRusIxZsCE41cughODn6N1Jdz-7HYx-NVnsZPYl7mxZTLbR_D9JcWvu8sFoPVCl-1Xg9YNAyb9mqM3sYvUwrYdDnqthUpFeMSWGFcpO0OMHCoTHNZSYY5BmG8x9hqdyH-RKevWvwUfK39j4HyNunr4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2780482865</pqid></control><display><type>article</type><title>Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan</title><source>PubMed Central</source><creator>Yesil, Ezgi Ersoy ; Yilmaz, Yusuf ; Yesil, Atakan ; Mese, Meral ; Kaya, Eda ; Bakir, Elif Ari</creator><creatorcontrib>Yesil, Ezgi Ersoy ; Yilmaz, Yusuf ; Yesil, Atakan ; Mese, Meral ; Kaya, Eda ; Bakir, Elif Ari</creatorcontrib><description>Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date.
We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as the control group through prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan.
Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, respectively (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, 95% confidence interval (CI): 1.039-1.208).
MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.</description><identifier>ISSN: 1307-5888</identifier><identifier>EISSN: 2757-7392</identifier><identifier>DOI: 10.14744/hf.2022.2022.0038</identifier><identifier>PMID: 36843889</identifier><language>eng</language><publisher>Turkey: Kare Publishing</publisher><ispartof>Hepatology Forum, 2023-01, Vol.4 (1), p.14-18</ispartof><rights>Copyright 2023 by Hepatology Forum.</rights><rights>Copyright 2023 by Hepatology Forum 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951894/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951894/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36843889$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yesil, Ezgi Ersoy</creatorcontrib><creatorcontrib>Yilmaz, Yusuf</creatorcontrib><creatorcontrib>Yesil, Atakan</creatorcontrib><creatorcontrib>Mese, Meral</creatorcontrib><creatorcontrib>Kaya, Eda</creatorcontrib><creatorcontrib>Bakir, Elif Ari</creatorcontrib><title>Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan</title><title>Hepatology Forum</title><addtitle>Hepatol Forum</addtitle><description>Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date.
We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as the control group through prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan.
Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, respectively (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, 95% confidence interval (CI): 1.039-1.208).
MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.</description><issn>1307-5888</issn><issn>2757-7392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVUctuFDEQtBCIrEJ-gAPykcsEP2b84IAURQSQIoEEnC3b084aZu3F9qw038BPM9kNEVy6D11VXd2F0EtKLmkv-_7NNlwywtipEMLVE7RhcpCd5Jo9RRvKiewGpdQZuqj1ByGEKUqooM_RGReq50rpDfr9pcDBTpA84BzwDpp1eYoej0sNc_It5tTZWrOPtsGIg21twVM8QMFjrGAr4JjwzzgmWHArNtX9ZFPDBXzcR0itvsVX2Jdca1fhqGcnXNs8LniuMd3hm-hK_upteoGeBTtVuHjo5-j7zftv1x-7288fPl1f3XaeD7x1QQgiiSbUhlEH59zYCwHUB0l8UN45rbQWXFJipaRusIxZsCE41cughODn6N1Jdz-7HYx-NVnsZPYl7mxZTLbR_D9JcWvu8sFoPVCl-1Xg9YNAyb9mqM3sYvUwrYdDnqthUpFeMSWGFcpO0OMHCoTHNZSYY5BmG8x9hqdyH-RKevWvwUfK39j4HyNunr4</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Yesil, Ezgi Ersoy</creator><creator>Yilmaz, Yusuf</creator><creator>Yesil, Atakan</creator><creator>Mese, Meral</creator><creator>Kaya, Eda</creator><creator>Bakir, Elif Ari</creator><general>Kare Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan</title><author>Yesil, Ezgi Ersoy ; Yilmaz, Yusuf ; Yesil, Atakan ; Mese, Meral ; Kaya, Eda ; Bakir, Elif Ari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-f66070901afd9fbbbd466e1cf70cf8cbb989963710a771b5a22aeaffb847f8663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yesil, Ezgi Ersoy</creatorcontrib><creatorcontrib>Yilmaz, Yusuf</creatorcontrib><creatorcontrib>Yesil, Atakan</creatorcontrib><creatorcontrib>Mese, Meral</creatorcontrib><creatorcontrib>Kaya, Eda</creatorcontrib><creatorcontrib>Bakir, Elif Ari</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology Forum</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yesil, Ezgi Ersoy</au><au>Yilmaz, Yusuf</au><au>Yesil, Atakan</au><au>Mese, Meral</au><au>Kaya, Eda</au><au>Bakir, Elif Ari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan</atitle><jtitle>Hepatology Forum</jtitle><addtitle>Hepatol Forum</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>4</volume><issue>1</issue><spage>14</spage><epage>18</epage><pages>14-18</pages><issn>1307-5888</issn><eissn>2757-7392</eissn><abstract>Metabolic dysfunction-associated fatty liver disease (MAFLD) is expected to be prevalent among kidney transplant recipients (KTRs). In this study, we evaluated the prevalence of MAFLD among KTRs, data that have not been investigated by any clinical study to date.
We included a total of 52 KTRs and 53 age-, sex-, and BMI-matched individuals as the control group through prospective consecutive recruitment. We detected the presence of hepatic steatosis and liver fibrosis using the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) defined by FibroScan.
Among the KTRs, 18 (34.6%) had metabolic syndrome. The prevalence of MAFLD among the KTRs and controls was 42.3% and 51.9%, respectively (p=0.375). The CAP and LSM values did not differ significantly between the KTRs and controls (p=0.222 and p=0.119). Among the KTRs, patients with MAFLD had significantly higher age, BMI, waist circumference, LDL, and total cholesterol levels (p<0.001, p=0.011, p=0.033, p=0.022, and p=0.029, respectively). In multivariable analysis, age was the only independent factor for MAFLD among the KTRs (OR: 1.120, 95% confidence interval (CI): 1.039-1.208).
MAFLD among KTRs did not show a significantly higher prevalence compared to the normal population. Further clinical studies with larger populations are needed.</abstract><cop>Turkey</cop><pub>Kare Publishing</pub><pmid>36843889</pmid><doi>10.14744/hf.2022.2022.0038</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1307-5888 |
| ispartof | Hepatology Forum, 2023-01, Vol.4 (1), p.14-18 |
| issn | 1307-5888 2757-7392 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9951894 |
| source | PubMed Central |
| title | Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T03%3A52%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevalence%20of%20metabolic%20dysfunction-associated%20fatty%20liver%20disease%20in%20kidney%20transplant%20recipients:%20A%20cross-sectional%20study%20using%20FibroScan&rft.jtitle=Hepatology%20Forum&rft.au=Yesil,%20Ezgi%20Ersoy&rft.date=2023-01-01&rft.volume=4&rft.issue=1&rft.spage=14&rft.epage=18&rft.pages=14-18&rft.issn=1307-5888&rft.eissn=2757-7392&rft_id=info:doi/10.14744/hf.2022.2022.0038&rft_dat=%3Cproquest_pubme%3E2780482865%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2780482865&rft_id=info:pmid/36843889&rfr_iscdi=true |